Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for the development of next generation biologic drugs that extend the efficacy, safety and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications.

Technology Platforms

Offers the potential of enhanced performance of peptide and protein drugs using polysialylation.

More about PolyXen


Established as novel, patent-protected, platform technology.

More about OncoHist

If you wish the view the Scheme Document and other related Documents, please click here.


Xenetic founder, Professor Gregory Gregoriadis, publishes semi-autobiography "Still the Cicadas Sing"

Product Pipeline

Xenetic is developing a biopharmaceutical pipeline with a multi-billion dollar market potential.

View our product candidates

Our Partnerships

Xenetic has collaborations with leading global biopharma companies, including Baxter International

More about the projects with some of our partners

Press Releases

Jan 16, 2015

Xenetic Biosciences to Hold Business Update Conference Call January 20th

Dec 19, 2014

Xenetic Biosciences Completes Enrollment of Second Cohort in Phase 2a Study with ErepoXen® for Anemia; Hemoglobin Levels Rise into Therapeutic Range over Time

View all press releases »